Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates
07:32pm, Thursday, 06'th May 2021
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th May 2021
EMERYVILLE, Calif., May 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 share
Will Dynavax Technologies (DVAX) Report Negative Earnings Next Week? What You Should Know
06:03pm, Thursday, 29'th Apr 2021
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
04:05pm, Thursday, 22'nd Apr 2021
EMERYVILLE, Calif., April 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report f
Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
04:01pm, Wednesday, 21'st Apr 2021
EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today ann
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
04:00pm, Wednesday, 21'st Apr 2021
Saint- Herb lain (France) , April 21 , 2 021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with signific
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
05:59pm, Tuesday, 20'th Apr 2021
Saint- Herb lain (France) , April 20 , 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significa
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
04:10pm, Monday, 19'th Apr 2021
EMERYVILLE, Calif., April 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announc
Why Dynavax Stock Jumped Today
04:12pm, Thursday, 15'th Apr 2021
Investors cheered good news from the company's COVID-19 vaccine partner.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)
08:19am, Friday, 09'th Apr 2021
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data
10:36am, Wednesday, 07'th Apr 2021
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Valneva's COVID-19 Vaccine Candidate Using Dynavax's Adjuvant Shows Positive Interim Results
09:38am, Tuesday, 06'th Apr 2021
Dynavax Technologies Corporation (NASDAQ: DVAX) has announced that Valneva SE reported initial results from Part A of the Phase 1/2 trial evaluating Valneva's COVID-19 vaccine candidate, VLA2001,
French vaccine maker Valneva to launch Phase 3 trial of COVID vaccine it's making with Dynavax after positive results
06:40am, Tuesday, 06'th Apr 2021
Dynavax Technologies Corp. said Tuesday that French vaccine maker Valneva plans to commence a Phase 3 trial of its inactivated COVID-19 vaccine candidate, VLA2001, with Dynavax's CpG 1018(TM) adjuvant
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
06:00am, Tuesday, 06'th Apr 2021
EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announce
